Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie,...
Year: 2025
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno...
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics
Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE,...
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief...
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company...
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total...
BioStem Technologies CEO to Present at Biotech Showcase 2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE)...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that...
The Ensign Group Closes on Expansion in Tennessee, Adds Its First Operation in Alabama
SAN JUAN CAPISTRANO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group...
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO...
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentationMarlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp....
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening...
Delota Reports Third Quarter Revenue of $10.3 Million; $29.9 Million for the Nine Months Ended 2025 and Third Consecutive Quarter of Positive Adjusted EBITDA
Highlights:Total revenue of $10.3 million for Q3 2025, reflecting YoY growth of 27% from the comparative quarter37% gross profit margin...
Hisense Ranked No.1 in MEA for Large-Screen and MiniLED TV Shipments
DUBAI, UAE, Jan. 2, 2025 /PRNewswire/ -- Hisense, a global leader in consumer electronics and home appliances, has achieved a...
SMART 2025: Shaping the Future of Wellness During CES Week
LAS VEGAS, Jan. 1, 2025 /PRNewswire/ -- AI Wellness proudly launches the SMART 2025 Initiative during CES Week, setting the stage for...